TABLE I.
Demographics (mean±SDs) of subjects in SARP
| RNAseq (BEC) Longitudinal | Microarray (BEC) Cross-sectional | WGS† | |||||||
|---|---|---|---|---|---|---|---|---|---|
| All | WGS | All | GWAS | Severe Asthma | Non-severe Asthma | Longitudinal Exacerbations | Non-Hispanic White | African American | |
| n | 156 | 114 | 155 | 120 | 426 | 531 | 273 | 1,016 | 622 |
| Age | 41±13 | 41±13 | 37±13 | 36±13 | 46±15 | 37±15 | 47±16 | 39±17 | 29±17 |
| Female, n (%) | 99 (63) | 74 (65) | 101 (65) | 80 (67) | 269 (63) | 353 (66) | 176 (64) | 656 (65) | 369 (59) |
| BMI | 30±8.1 | 30±8.7 | 30±6.8 | 30±7.0 | 31±7.7 | 28±7.6 | 31±7.9 | 29±7.9 | 30±11 |
| Race (Non-Hispanic White/African American/Other*), % | 67/24/9 | 65/26/9 | 62/29/9 | 60/29/11 | 100/0/0 | 100/0/0 | 100/0/0 | 100/0/0 | 0/100/0 |
| Baseline % predicted FEV1 | 82±21 | 76±20 | 76±22 | 76±23 | 66±22 | 84±17 | 73±21 | 77±21 | 78±20 |
| Baseline FEV1/FVC | 0.73±0.10 | 0.70±0.10 | 0.72±0.12 | 0.71±0.13 | 0.66±0.13 | 0.75±0.09 | 0.69±0.11 | 0.72±0.12 | 0.72±0.11 |
| Asthma status (Control/Non-severe/Severe), n | 42/49/65 | 0/49/65 | 27/78/50 | 19/60/41 | 0/0/426 | 0/531/0 | 0/111/162 | 0/564/451 | 0/270/252 |
| Age Onset of Asthma<18 yrs, n (%) | 77 (68) | 77 (68) | 88 (71) | 69 (68) | 238 (56) | 348 (66) | 164 (60) | 645 (64) | 394 (75) |
Note: BEC: bronchial epithelial cell brushing; Microarray: Agilent Whole Human Genome Microarray 4x44K v2; WGS: whole-genome sequence; GWAS: genome-wide association study.
*
Other races include Hispanic, Asian, American Indian, and mixed.
†
1,016 non-Hispanic Whites and 622 African Americans in SARP longitudinal and cross-sectional cohorts with WGS were used for LD calculation; Among 1,016 non-Hispanic Whites, 957 adults (age ⩾ 12 yrs) (426 with severe asthma vs. 531 with non-severeasthma) were included in the genetic association analysis of asthma severity; 273 adults in the longitudinal cohort were included in the genetic association analysis of longitudinal asthma exacerbations.